TORREYPINES AND EISAI ENTER INTO A NEW ALLIANCE REGARDING A NOVEL GENETIC RESEARCH PROGRAM FOR ALZHEIMER'S

Eisai Co., Ltd. (President & CEO: Haruo Naito) and TorreyPines Therapeutics, Inc. (President & CEO: Neil Kurtz, M.D.) today jointly announced the signing of a new research agreement that focuses on the discovery of genes responsible for late onset Alzheimer's disease. This latest agreement marks the continuation of Eisai's support for this program that began in 2001. A second collaboration agreement between TorreyPines and Eisai was signed in February of this year to support the discovery of small molecules that lower A-beta42, a peptide involved in the creation of amyloid plaques, a hallmark of Alzheimer's disease.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-11-2005/0004165209&EDATE=)